

Atty Dkt. No.: STAN130
USSN: 09/710,841

AMENDMENTS

In the Claims:

Claims 1-15 (Canceled).

16. (Currently Amended) A method for modulating at least one pharmacokinetic property of a drug upon administration to a host, said method comprising:

administering to said host an effective amount of a bifunctional molecule of less than about 5000 daltons consisting of said drug or an active derivative thereof and a pharmacokinetic modulating moiety, wherein said pharmacokinetic modulating moiety binds to an intracellular protein and said bifunctional molecule has at least one modulated pharmacokinetic property upon administration to said host as compared to a free drug control that comprises said drug;

whereby at least one pharmacokinetic property of said drug upon administration to said host is modulated as compared to the free drug control.

17. (Original) The method according to Claim 16, wherein said pharmacokinetic property is selected from the group consisting of half-life, hepatic first-pass metabolism, volume of distribution and degree of blood protein binding.

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Currently Amended) The method according to Claim 16, wherein said drug targets is a protein.

22. (Original) The method according to Claim 16, wherein said bifunctional molecule is administered as a pharmaceutical preparation.

Atty Dkt. No.: STAN130
USSN: 09/716,841

23. (Currently Amended) A method for modulating the half life of a drug upon administration to a host, said method comprising:

administering to said host an effective amount of a bifunctional molecule of less than about 5000 daltons consisting of said drug or an active derivative thereof and a half-life modulating moiety, wherein said half-life modulating moiety binds to an intracellular protein and said bifunctional molecule has a modified half-life upon administration to said host as compared to a free drug control that comprises said drug;

whereby the half life of said drug upon administration to said host is modulated as compared to the free drug control.

24. (Canceled)

25. (Canceled)

26. (Currently Amended) The method according to Claim 23, wherein said drug targets is a protein.

27. (Original) The method according to Claim 23, wherein said bifunctional molecule is administered as a pharmaceutical preparation.

28. (Currently Amended) A method for modulating the hepatic first-pass metabolism of a drug upon administration to a host, said method comprising:

administering to said host an effective amount of a bifunctional molecule of less than about 5000 daltons consisting of said drug or an active derivative thereof and a hepatic first-pass metabolism modulating moiety, wherein said hepatic first-pass metabolism modulating moiety binds to an intracellular protein and said bifunctional molecule has a modified hepatic first-pass metabolism upon administration to said host as compared to a free drug control that comprises said drug;

whereby the hepatic first-pass metabolism of said drug upon administration to

Atty Dkt. No.: STAN130
USPN: 09/710,841

said host is modulated as compared to the free drug control.

29. (Canceled)

30. (Canceled)

31. (Currently Amended) The method according to Claim 28, wherein said drug targets is a protein.

32. (Original) The method according to Claim 28, wherein said bifunctional molecule is administered as a pharmaceutical preparation.

Claims 33 to 50. (Canceled)

51. (Currently Amended) A method for modulating at least one pharmacokinetic property of a drug upon administration to a host, said method comprising:

administering to said host an effective amount of a bifunctional molecule of less than about 5000 daltons consisting of said drug or an active derivative thereof and a pharmacokinetic modulating moiety joined by a linking group, wherein said pharmacokinetic modulating moiety binds to an intracellular protein and said bifunctional molecule has at least one modulated pharmacokinetic property upon administration to said host as compared to a free drug control that comprises;

whereby at least one pharmacokinetic property of said drug upon administration to said host is modulated as compared to the free drug control.

52. (Previously presented) The method according to Claim 51, wherein said pharmacokinetic property is selected from the group consisting of half-life, hepatic first-pass metabolism, volume of distribution and degree of blood protein binding.

53. (Canceled)

Atty Dkt. No.: STAN130
USSN: 09/716,841

54. (Canceled)

55. (Currently Amended) The method according to Claim 51, wherein said drug targets is a protein.

56. (Previously Presented) The method according to Claim 51, wherein said bifunctional molecule is administered as a pharmaceutical preparation.

57. (Currently Amended) A method for modulating the half life of a drug upon administration to a host, said method comprising:

administering to said host an effective amount of a bifunctional molecule of less than about 5000 daltons consisting of said drug or an active derivative thereof and a half-life modulating moiety joined by a linking group, wherein said half-life modulating moiety binds to an intracellular protein and said bifunctional molecule has a modified half-life upon administration to said host as compared to a free drug control that comprises said drug;

whereby the half life of said drug upon administration to said host is modulated as compared to the free drug control.

58. (Canceled)

59. (Canceled)

60. (Currently Amended) The method according to Claim 57, wherein said drug targets is a protein.

61. (Previously Presented) The method according to Claim 57, wherein said bifunctional molecule is administered as a pharmaceutical preparation.

Atty Dkt. No.: STAN130

USSN: 09/710,841

62. (Currently Amended) A method for modulating the hepatic first-pass metabolism of a drug upon administration to a host, said method comprising:

administering to said host an effective amount of a bifunctional molecule of less than about 5000 daltons consisting of said drug or an active derivative thereof and a hepatic first-pass metabolism modulating moiety joined by a linking group, wherein said hepatic first-pass metabolism modulating moiety binds to an intracellular protein and said bifunctional molecule has a modified hepatic first-pass metabolism upon administration to said host as compared to a free drug control that comprises said drug;

whereby the hepatic first-pass metabolism of said drug upon administration to said host is modulated as compared to the free drug control.

63. (Canceled)

64. (Canceled)

65. (Currently Amended) The method according to Claim 63, wherein said drug targets is-a protein.

66. (Previously Presented) The method according to Claim 63, wherein said bifunctional molecule is administered as a pharmaceutical preparation.